Qingdao Biopeptek Co., Ltd.: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from Qingdao Biopeptek Co., Ltd.?
Yes. FDA’s import refusal records list 4 refused shipment lines declared as made by Qingdao Biopeptek Co., Ltd. (China) whose FDA product code names semaglutide and tirzepatide, from Dec 4, 2023 to Jan 25, 2024. 3 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Country
- China
- City in FDA records
- Qingdao
- FEI numbers on the lines
- 3009110908
- Refused lines
- 4
- Lines with an Import Alert 66-80 API or powder code
- 3
- Drugs named in the product codes
- Semaglutide, Tirzepatide
- Refusal dates
- Dec 4, 2023 to Jan 25, 2024
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Qingdao Biopeptek Co., Ltd. is on it.
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| Jan 25, 2024 | China | 61PCR72 SEMAGLUTIDE (ANTI-DIABETIC) | NonSterile Powder | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | AEK-3647198-3/11/1 |
| Dec 6, 2023 | China | 61PCT72 SEMAGLUTIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | AEK-3571990-3/11/1 |
| Dec 6, 2023 | China | 61PCT74 TIRZEPATIDE (ANTI-DIABETIC) | Active Pharm Ingred/Chems for Rx Compounding | DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | AEK-3572197-4/11/1 |
| Dec 4, 2023 | China | 61PAY72 SEMAGLUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | AEK-3647249-4/11/1 |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| DIRSEXMPT: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug within the meaning of Section 201(g) and it lacks adequate directions for use. | 3 |
| FALSEDRUG: The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a drug which is misbranded within the meaning of section 502(a)(1) in that its labeling is false or misleading. | 3 |
| LACKS FIRM: The article is in package form and appears to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. | 2 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.
4 lines from FDA files read Nov 15, 2026.